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Side Effects of Corporate Greed: Pharmaceutical
Companies Need a Dose of Corporate Social
Responsibility
Martin L. Hirsch*
I.

INTRODUCTION

“The point is, ladies and gentleman, that greed . . . for
lack of a better word . . . is good. Greed is right. Greed
works. Greed clarifies, cuts through, and captures the
essence of the evolutionary spirit.”1
When it comes to health care and pharmaceuticals,
greed is not good. In the world of health care, where
patients rely on their doctors to do what is best for them,
there is no place for greed.2 Corporate governance in
pharmaceutical
companies
that
focuses
on
the
shareholder’s bottom line is completely inconsistent with
health care, medicine and access to pharmaceuticals,
where the patient should come first.3 This Article discusses
how the corporate governance of pharmaceutical
companies negatively affects health care and access to
medicine world wide.4
*

©

2008 Martin L. Hirsch.
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1
1. WALL STREET (Amercent Films 1987).
2
2. It has long been held that the relationship of patient and physician is
one of trust and confidence. See 36A CAL. JUR. 3d Healing Arts and
Institutions § 352.
3
3. The Hippocratic Oath, a pledge taken by most graduating medical
students, states in part, “I will apply, for the benefit of the sick, all
measures that are required, avoiding those twin traps of overtreatment
and therapeutic nihilism.” The Hippocratic Oath–Modern Version,
http://www.pbs.org/wgbh/ nova/doctors/oath_modern.html. (Last visited
February 24, 2008). The Hippocratic Oath also states that “[doctors] will
remember that there is art to medicine as wall as science, and that
warmth, sympathy, and understanding may outweigh the surgeon’s knife
or the chemist’s drug.” Id.
4
4. It notes that corporations are accountable to their shareholders, and
that stakeholders of the corporation are not protected by corporate law,
but protected by other regulatory law. In the context of this article the
argument would be that pharmaceutical companies are accountable to
their shareholders’ interests even before their customers’, and if a
customer is injured by a product, that customer has a remedy under tort
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By adhering to the typical shareholder model of
corporate governance, the pharmaceutical companies’
ethics5 do not always align with that which a patient might
expect from their health care provider.6 The shareholder
model of corporate governance encourages pharmaceutical
companies to maximize shareholder profit. Transversely,
patients and others seeking health benefits and medical
care from the products of the pharmaceutical companies
are concerned with their own health and well being.7
Therefore, a change from the shareholder model approach
of corporate governance to one which aligns the interests of
the company with that of their customers would better
serve the medical needs the pharmaceutical companies’
customers.
This Article argues that patient health is good, patient
health is right, and that patient health works.
Pharmaceutical companies should find value in doing what
is best for patients rather than their shareholders’ bank
accounts. Such a system where patient health is the
highest value can be implemented through corporate social
responsibility8 which shifts the corporations’ duty from
maximizing shareholder profits to considering, and
providing for, customer and community needs. Part I of this
Article discusses several examples of the effects of the
current corporate governance structure in pharmaceutical
companies. Part II examines different international models
of corporate governance, specifically looking at systems
promulgated by the United Nations and the European
Union.
Part III considers whether these systems of
corporate social responsibility ultimately provide a means to
change the corporate governance of the pharmaceutical
companies in order to recognize health as a fundamental
608

law. Henry Hansmann & Reinier Kraakman, The End of History for
Corporate Law, 89 GEO. L.J. 439 (2001).
5
5. Ethics, as used here, means the moral conviction to do what is best
for the patients at all times.
6
6. Pharmaceutical company refers to companies that produce medicine
and drugs to treat various diseases, ailments and health issues, and follow
the shareholder model of corporate governance.
7
7. See Sacha Bonsor, Trust Me I’m a Patient, TIMES (London), May 1,
2007, at 4 (stating that patients are led to believe that doctors are right
about their diagnoses and treatment recommendations).
8
8. Corporate social responsibility refers to the dedication of businesses
to the interests of its community, customers, and society at large.
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human right and shift focus from maximizing shareholder
profit to maximizing world health.

A. PROFITS VALUED OVER LIVES
A young man sits outside his house in Northern India,
suffering from the effects of leishmaniasis. He shows signs
of fever, has an enlarged spleen, and the whites of his eyes
are yellow. This disease will attack his immune system and
leave him susceptible to infection, most likely tuberculosis.
If he is not treated, he will die. His father, who pulls a
rickshaw, worked endlessly to save enough money to save
his son. His family has already spent several months’ of
income on treatment, only to learn that the treatment they
worked so hard to acquire would fail. The drug they could
afford had lost its effectiveness, and would not save the
young man. The drug that doctors formerly used to treat
the disease had become outdated.9
A man in South Africa who contracted cerebrospinal
meningitis during the annual outbreak suffers at home with
no option for treatment. His family cannot afford the cost
for his medication, $65 (USD). The treatment cost more
than five wage earners in the family would make in two
weeks. The family did not have any money to spare after
purchasing food and paying for school.10
1. Treating Diseases of the Poor
What if Scrooge had the power to cure disease, but
9

9. Drug companies stopped researching drugs for tropical diseases such
as leishmaniasis due to economic reasons, not scientific ones. According
to pharmaceutical companies there is not a market for medicine that treat
tropical diseases. Tropical diseases such as malaria and leishmaniasis
effect people in tropical areas of the world, which are overwhelmingly
poor areas. There is a market for the medicine in the sense that millions of
people die from these diseases every year showing how needed the drugs
are. But there is not a market for these drugs in the sense that the people
suffering from the diseases are poor and generally could not afford the
treatment. Isabel Hilton, A Bitter Pill for the World’s Poor, GUARDIAN, Jan. 5,
2000, at 20.
0
10. The author of the article, Mr. Boudreau, was friends with this sick
man. The man’s family contacted Mr. Boudreau who took the man to the
hospital and paid the $65 for treatment. After his friend received the
treatment, the author asked the doctor what would have happened if he
had not received treatment. The doctor’s response was, “he would be
allowed to die.” Ned Boudreau, Devil’s Bargain: Africa and the
Pharmaceutical Companies, ZNET DAILY COMMENT., Oct. 2, 2002,
http://www.zmag.org/ sustainers/content/2002-10/02boudreau.cfm.
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sacrificed that power in order to maximize profits?11
In the stories told above, and millions others like them
emanating from the developing world12 poverty is the true
cause of death.13 Either those who contract the disease
cannot afford the treatment, or medicine is not available
because pharmaceutical companies stopped improving
outdated drugs.14 Pharmaceutical companies have been
accused of keeping lifesaving treatment beyond the reach
of the world’s poor, by keeping prices high, even for drugs
to treat the poor.15 Even though there is demand for the
drugs, there is no profit in producing them, so
pharmaceutical companies have simply stopped.16
Drug companies are criticized for focusing their
research on such matters as baldness, toe fungus, and
erectile dysfunction rather than global epidemics, especially
those plaguing poor countries.17 Rather than focus on curing
life threatening diseases, global pharmaceutical companies
research and produce what are called lifestyle drugs,
because there is far more money to be made selling these
types of drugs.18 Lifestyle drugs are sold for large profits,
610

1

11. Joseph E. Stiglitz, Scrooge and Intellectual Property Rights, 333 BRIT.
MED. J. 1279, 1279 (2006).
2
12. Developing countries are economically underdeveloped countries
that share the common characteristics of poverty, high birthrates, and
economic dependence on developed countries. See Third World:
Definitions
and
Descriptions,
http://www.thirdworldtraveler.com/General/ThirdWorld_def.
html
(last
visited Feb. 27, 2008).
3
13. Hilton, supra note 9, at 1.
4
14. Id.
5
15. Oxfam: Drug Firms Waging War on Poor, CNN.COM, Feb. 12, 2001,
http://archives.cnn.com/2001/WORLD/europe/UK/02/12/oxfam.drugs/.
6
16. The recent trend in pharmaceutical companies is more spending on
research and development, but production of fewer drugs. The pipeline of
new drugs is beginning to run out. This is creating a growing urgency to
find the next blockbuster drug in order to increase profits for the industry
that a recent estimate found to have lost $1 trillion in future profitability.
The result of this focus on finding the next blockbuster drug to reverse the
economic trend is an increased focus on lifestyle drugs that sell for high
profits in the United States, and a move away from developing better
drugs to treat tropical diseases. Billion Dollar Pills, ECONOMIST, Jan. 25, 2007,
at 70-71.
7
17. Drugs, such as the ones described above that treat toe fungus and
baldness, that do not necessarily treat harmful disease, are referred to as
“lifestyle drugs.” Ken Silverstein, Millions for Viagra, Pennies for Diseases
of the Poor, NATION, July 19, 1999, at 13.
8
18. Id.

MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE
TECH. 607-636 (2008).

AND

LEGAL POLICY ," 9(2) MINN. J.L. SCI. &

2008]

CORPORATE SOCIAL RESPONSIBILITY
611
whereas drugs to treat the poor amount to a losing
endeavor because the people who need the drugs cannot
afford to pay the high prices the pharmaceuticals
companies charge in order to maximize profits.19
In 1998, 6.1 million people in developing countries died
from diseases that are preventable, and curable, including
malaria, tuberculosis, and lower-respiratory-infections.20
These people died because the drugs used to treat their
diseases are either no longer effective, nonexistent, or too
expensive.21 Pharmaceutical companies are currently
discontinuing their research and development of drugs to
treat tropical diseases allowing the former treatments to
become outdated.22 Of the forty-one important drugs used
to treat tropical diseases, diseases primarily affecting
developing countries, none were discovered in the 1990s
and all but six were discovered before 1985.23 Sleeping
sickness, a disease that effects 300,000 Africans each year
can only be treated with the same drug that was used to
treat it seventy years ago.24 The last drug company that
made a more effective treatment discontinued the product
because it was not profitable.25 The only treatment that
remains is the seventy-year-old concoction of what amounts
to arsenic and anti-freeze, which kills 5% of the people
injected with it.26
9

19. In 2002, pharmaceutical companies that were members of the
Fortune 500 out earned all the other Fortune 500 companies by a
considerable margin. Profits were measured three ways, and in each
category the drug companies had higher profits. Measuring profits as a
percentage of revenue the drug companies earned more by nearly 14%,
profits as a percentage of assets drug companies earned more by nearly
12%, and profits as a percentage of equity drug companies earned more
by over 17%. NEAL PATTISON & LUKE WARREN, PUB. CITIZEN CONGRESS WATCH, 2002
DRUG INDUSTRY PROFITS: HEFTY PHARMACEUTICAL COMPANY MARGINS DWARF OTHER INDUSTRIES
1
(2003),
available
at
http://www.citizen.org/congree/reform/drug_industry/corporate/
articles.cfm?ID=9923.
0
20. Silverstein, supra note 17, at 13.
1
21. Hilton, supra note 9, at 1.
2
22. JEAN O. LANJOUW & MARGARET MACLEOD, STATISTICAL TRENDS IN PHARMACEUTICAL
RESEARCH
FOR
POOR
COUNTRIES,
2
(2005),
available
at
http://www.who.int/intellectualproperty/studies/en/Lanjouw_Statistical
%20Trends.pdf.
3
23. Silverstein, supra note 17, at 14.
4
24. Donald G. McNeil, Jr., Drug Companies and the Third World: A Case
Study in Neglect, N.Y. TIMES, May 21, 2000, at 1.
5
25. Id. at 2.
6
26. Id.
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“People ask me how we could have been so stupid so as
to sue Nelson Mandela . . . I say we had to, Mother Theresa
was already dead.”27
A pharmaceutical company representative told this joke
at a conference referring to the lawsuit thirty-nine
pharmaceutical companies brought to stop the South
African government from importing cheap antiviral generic
drugs to treat citizens infected with AIDS who otherwise
could not afford treatment.28 The pharmaceutical companies
eventually dropped the lawsuit, but the drugs remained too
expensive for the South African government to implement
an effective treatment program.29
The world’s major pharmaceutical companies are
involved in a similar fight against Brazil to stop its
production of generic drugs to treat AIDS patients.30 Brazil
instituted a government funded medical program whereby
the government would provide free AIDS treatment to those
who needed it.31 The only way the government could afford
to continue the program was by producing generic versions
of the needed drugs.32 Since Brazil instituted the program it
cut the death rate from AIDS in half.33 The drug companies
oppose the program because the drugs Brazil produces are
protected by patents.34
Some say the stance taken by the pharmaceutical
companies against providing affordable treatment of AIDS
shows they value wealth over health.35 The problem facing
poor countries fighting the AIDS epidemic is the only way to
7

27. Amy Kapcynski, Strict International Patent Laws Hurt Developing
Countries, YALE GLOBAL, Dec. 16, 2002, http://yaleglobal.yale.edu/display.
article?id=562.
8
28. Id.
9
29. Philippe Riviere, Patently Wrong: Southern Sickness, Northern
Medicine, LE MONDE DIPLOMATIQUE , July 2001, at 1, http://mondediplo.com/
2001/07/07aids.
0
30. Indira A.R. Lakshmanan, Drug Costs Imperil Brazil AIDS Fight, BOSTON
GLOBE, Jan. 3, 2007, at 1, 2.
1
31. Id. at 1.
2
32. Id.
3
33. The Other Drug War: Pharmaceutical Companies and WTO sue Brazil
and South Africa to Protect Prices and Patents (Democracy Now!
Broadcast
Feb.
15,
2001),
available
at
http://www.democracynow.org/article.pl?sid=03/ 04/07/0156254.
4
34. Id.
5
35. Oxfam: Drug Firms Waging War on Poor, supra note 15, at 1.
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provide affordable drugs to save lives is to buy or produce
generic antiviral drugs.36 New antiviral drugs cost $17,000
(USD) per year, per patient, whereas older generic versions
of similar treatment cost only hundreds of dollars per year.37
The option seems to be to either continue producing generic
treatment and save lives, or switch to patented drugs and
let the people who cannot afford the treatment to die.38

3. Nigeria Sues Pfizer
The drug companies are involved in another
international lawsuit.
This time, however, a foreign
government sued a major drug company.39 During an
outbreak of meningitis in 1996, Pfizer provided Trovan to
treat the disease.40 The Nigerian government sued Pfizer for
$7 billion (USD) on behalf of the families of children who
died or suffered side effects for alleged unauthorized testing
6

36. See The Other Drug War, supra note 33. See generally Lakshmann,
supra note 30, at 2.
7
37. Lakshmanan, supra note 30, at 1.
8
38. One of the major issues related to the AIDS drugs, as well as the
need to provide other types of drugs to poorer nations, are the patent and
intellectual property issues. To address these issues the World Trade
Organization (WTO) member countries created an agreement on TradeRelated Aspects of Intellectual Property Rights (TRIPS). TRIPS attempt to
create a balance between the long term goal of providing incentives for
future research and development of new drugs by protecting patent
rights, and the short term goal of allowing access to existing, patented,
drugs in order to provide needed medicine. The Doha Declaration, in
which participating governments agreed on the application of TRIPS,
interprets TRIPS in a way to support public health. This allows
governments to act in ways that are motivated by the need to protect
public health. A large part of this is allowing countries the right to grant
compulsory licensing in an emergency situation to either import or
produce generic medicines. The countries have the freedom to decide
what constitutes an emergency. See generally TRIPS and Pharmaceutical
Patents:
Fact
Sheet,
http://www.wto.org/english/tratop_e/
trips_e/factsheet_pharm00_e.htm (last visited Feb. 28, 2008); The Doha
Declaration Explained, http://www.wto.org/english/tratop_e/dda_e/doha
explained_e.htm#top (last visited Feb. 28, 2008); TRIPS and Public Health,
Alternative
Law
Forum,
http://www.altlawforum.org/PUBLICATIONS/
document.2004-12-18.5846929564 (last visited Feb. 28, 2008) (discussing
corporate social responsibility, an alternative to TRIPS); infra notes 87–110
and accompanying text.
9
39. Faith Jones, Nigeria Sues Pfizer Over Drug Trial Scandal, SCIDEV.NET,
June 6, 2007, http://www.scidev.net/content/news/eng/nigeria-sues-pfizerover-drug-trial-scandal.cfm.
0
40. Nigeria Sues Drugs Giant Pfizer, BBC NEWS, June 5, 2007, http://
news.bbc.co.uk/2/hi/africa/6719141.stm.
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of Trovan.41 Specifically, the government alleges that Pfizer
administered Trovan to 233 children, killing 196 of them.42
Thirty-seven children survived the use of Trovan, but they
all suffered serious health problems such as deafness,
paralysis, brain damage, loss of sight, and slurred speech.43
Pfizer argues that they obtained verbal consent from
parents.44 However, at the time, Trovan had only been
approved for use by adults in the United States, and had
never been given to children.45 Regardless of which side
wins the lawsuit, it is clear that children died and Trovan
caused those deaths.46 Pfizer does not argue that treating
the children with Trovan was an experiment; it instead
asserts that it had approval to conduct such an
experiment.47 Nonetheless the facts indicate that Pfizer
experimented with those children’s lives.
614

B. BOTTOM LINE THINKING DOES

NOT

SPARE U.S. PATIENTS

A fourteen-year-old boy in Michigan rides his skateboard
outside his parents’ house when he suddenly collapses. He
had a heart attack. He later died. The chief pathologist who
examined him concluded that the boy’s blood vessels
showed scarring and tissue growth, commonly associated
with chronic stimulant use. The medical examiner said that
ten years of Ritalin use was the likely cause of the gradual
damage to the boy’s nervous system, ultimately leading to
his heart attack and his death.48
The allegations facing drug companies are not only
coming from abroad. Many stories like the one above have
surfaced domestically, indicating the trend of valuing profit
1

41. Id.
42. Jones, supra note 39.
3
43. Id.
4
44. Nigeria Sues Drugs Giant Pfizer, supra note 40.
5
45. Joe Stephens, Panel Faults Pfizer in ‘96 Clinical Trial in Nigeria, WASH.
POST, May 7, 2006, at A1.
6
46. Id.; Jones, supra note 39; Nigeria Sues Drugs Giant Pfizer, supra note
40.
7
47. Stephens, supra note 45, at A1.
8
48. Jeff Levine, Boy’s Death Linked to Ritalin, WEBMD MED.NEWS, Apr. 18,
2000,
http://www.webmd.com/news/20000418/boys-death-linked-toritalin; See also Death from Ritalin, http://ritalindeath.com/ADHD-DrugDeaths.htm (last visited Feb. 10, 2008) (memorializing children whose
deaths are linked to using ADD and ADHD treatment drugs such as Ritalin,
Desipramine, Stratters, and Concerta whose causes of death were either
heart related or suicide linked to prescription drug use).
2
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over public health exists in the United States. This trend is
most evident in direct-to-consumer advertising, and overprescription of potentially harmful drugs.49
A 2005 report shows that pharmaceutical companies
influence doctors’ diagnoses in an effort to improve their
bottom lines. Researchers at Dartmouth Medical School
estimate tens of millions more Americans were diagnosed
with a sickness or health problem during the 1990s than
ever before.50 The criteria used to make a diagnosis have
been changed in order to classify more healthy people as
sick.51 Changing the criteria of what is considered sick
resulted in tens of millions more customers for drug
companies.52 The report uncovered the fact that
pharmaceutical companies give money to members of the
World Health Organization, U.S. National Institute of Health
and some of America’s most prestigious medical societies
for these institutions to promote the pharmaceutical
industry’s agenda.53 As a result, today three in four
Americans are considered to have at least one disease, but
millions of these people are truly not sick, resulting in sales
of drugs to people who do not need them, but can afford to
pay for them.54 Remember: the opposite is true in
developing countries where people truly need the drugs,
but cannot afford them.

9

49. See generally Susan Kelleher & Duff Wilson, The Hidden Big Business
Behind your Doctor’s Diagnosis, SEATTLE TIMES, June 26, 2005, at A1
(describing the influences of the pharmaceutical industry on drug and
treatment guidelines).
0
50. See id.
1
51. For example, the threshold weight to be considered obese might be
lowered by several pounds, or the threshold to be diagnosed with
hypertension lowered by several blood pressure points. Id.
2
52. Id.
3
53. Id. See also Jerry Avorn, Dangerous Deception—Hiding the Evidence
of Adverse Drug Effects, 355 NEW ENG. J. MED. 2169 (2006). Doctor Avorn
recalls a conversation with a hospital administrator which illustrates the
effect the pharmaceutical companies have over doctors, and the
prescriptions they write. Dr. Avorn remembered the Administrator
describing how well the hospital’s grand-rounds worked because “the drug
companies find the speakers, pay their honoraria, and provide free food
for the doctor which helps a lot with attendance.” Id. Dr. Avorn goes on to
explain what a good deal this actually was for the pharmaceutical
companies, because the doctors who attended would go on to prescribe
the drugs promoted at that grand-round. Id.
4
54. Kelleher &Wilson, supra note 49.
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1. Dangerous Side Effects of Commonly Used Drugs 55
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Drug sales indicate that America is on its way to
becoming a drug-dependent nation. Between 1998 and
2000, sales of anti-depressant drugs increased 73%, and
sales of analeptics, drugs that stimulate the central nervous
system like Ritalin and Adderall, increased 167%.56 British
drug officials, as well as the Food and Drug Administration,
warned physicians about the risks associated with the antidepressants Paxil, which has the potential to prompt
teenagers and kids to consider suicide.57 Moreover, there
are ample documented instances of youth deaths linked to
Ritalin and anti-depressants.58 Nonetheless, use of these
drugs continue to skyrocket.59
Three independent studies tested the effects of Ritalin
use in humans. The results of one test concluded that using
prescription stimulants during childhood makes children
more susceptible to cocaine use as young adults.60 Another
study found that children treated for ADHD with prescription
stimulants had a 9% risk of developing psychotic symptoms,
while the control group—children who did not use those
drugs—showed zero signs of developing psychotic
symptoms.61 A final study found that stimulants can cause
growth retardation, depression and obsessive compulsive
disorder.62 Critics of the use of stimulants to treat ADHD and
5

55. Many commonly prescribed drugs carry harmful side effects. See
generally Avorn, supra note 53; Consumers Union, Prescription for
Change,
http://www.consumersunion.org/campaigns/prescriptionforchange/004320
indiv.html (last visited Jan. 30, 2008). To discuss each drug and its side
effects, however, is beyond the scope of this article.
6
56. Lou Dobbs, We Need a War vs. Legal Drugs, N.Y. DAILY NEWS, Sept. 28,
2003, at 14.
7
57. Id. The diet drug Fen-phen is yet another example of a prescription
drug that manifested harmful side effects in its users. See David J.
Morrow, Fen-phen Maker to Pay Billions in Settlement of Diet-Injury Cases,
N.Y. TIMES, Oct. 8, 1999, at 1.
8
58. Death from Ritalin, supra note 48 (describing the deaths of a number
of children “as a direct result of using psychotropic drugs used for ADD
and ADHD”).
9
59. Dobbs, supra note 56.
0
60. Peter R. Breggin & Fred A. Baughman Jr., Questioning the Treatment
for ADHD, 291 SCIENCE 595, 595 (2001).
1
61. Id.
2
62. Id. See also Gabrielle Weiss & Lily Hechtman, The Hyperactive Child
Syndrome, 205 SCIENCE 1348, 1348–54 (1979) (discussing a study
concluding that stimulant drugs can suppress growth and recommending
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ADD point to the fact that these stimulants enhance
obsessive compulsive behavior while suppressing a child’s
spontaneous behavior, such effects are then mistaken as
improved attention.63
There has also been an increase in the use of statin
drugs which are used to lower cholesterol in adults.64 A
change in the guidelines of what it means to have high
blood pressure increased the market for statin drugs.65 Nine
experts on cholesterol wrote these guidelines.66 Of these
nine experts, six of them have financial ties to the
pharmaceutical companies that produce the most
commonly used statin drugs.67 The more common side
effects from statin drugs are liver damage and muscle
aches.68 Muscle symptoms are the most common side
effects. This side effect is called “myopathy” and results in
actual damage to muscle tissue.69 Other less common side
effects include decrease in memory or concentration,
depression and irritability, pain other than muscle pain, and
peripheral neuropathy or tingling and numbness.70
In yet another example of prescription drugs harming
their users, cyclo-oxygenase-2 (COX 2) inhibitors were
found to be harmful. In 2005, a panel of doctors advised the
FDA that all COX 2 inhibitors should come with a “black
box” warning that these drugs increase chances of heart
attacks and strokes.71 The most popular COX 2 inhibitors
are Vioxx, Celebrex, and Bextra, which are prescribed to
treat arthritis.72 A story from 2005 estimated that Merck
alone faced nearly 7,000 state and federal lawsuits brought
lower dosages and periodic breaks in treatment to prevent the side effect
from occurring).
3
63. See, e.g., Breggin & Baughman, supra note 60.
4
64. See generally, Big Bucks, Big Pharma: Marketing Disease & Pushing
Drugs, (Democracy Now! broadcast Jan. 19, 2007), available at
http://www. democracynow.org/article.pl?sid=07/01/19/1432236.
5
65. Id.
6
66. Id.
7
67. Id.
8
68. The UCSD Statin Study, Statin Adverse Effects, http://medicine.ucsd.
edu/SES/adverse_effects.htm (last visited Jan. 30, 2008).
9
69. Id.
0
70. Id.
1
71. Leanne Lenzer, FDA Advisers Warn: COX 2 Inhibitors Increase Risk of
Heart Attack and Stroke, 330 BRIT. MED. J., 440, 440 (2005).
2
72. Id.
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by people allegedly harmed by using Vioxx.73 Merck, the
maker of Vioxx, voluntarily pulled the drug from the shelves
when it learned that the drug doubled the chance of heart
attack after eighteen months of use.74
618

2. Dangers of Direct-to-Consumer Advertising
Aside from changing the guidelines to diagnosis certain
diseases, drug companies now market not just treatments,
but health conditions themselves.75
Direct-to-consumer
advertising is defined as “any promotional effort by a
pharmaceutical company to present prescription drug
information to the general public in the lay media.” 76 This
marketing normalizes obscure disorders, presenting the
conditions as common.77 Direct-to-consumer advertising
leads people to believe they suffer from certain disorders or
diseases simply based on the way the advertisement shows
an uncommon disease in a normal light.78
These drugs certainly help people who truly suffer from
the afflictions they are designed to treat. However,
advertising the drug in a way that makes it seem like these
diseases affect any person who has felt shy in a social
setting, restless at night, or tense, causes people who hear
the advertisements to worry that they have a serious
disease if they show any of the described symptoms. After
hearing an advertisement, listeners will self-diagnose, or
become concerned that they need the drug.79
A survey of people who are exposed to direct-toconsumer advertising revealed that one-quarter of people
ask their doctors for the actual drug they heard advertised.
Of those people, three-quarters received the requested

3

73. Expert: Vioxx Use Causes Heart Attacks, CBS NEWS, Dec. 2, 2005,
http://www.cbsnews.com/stories/2005/12/02/ap/business/mainD8E8C3V0E
.shtml.
4
74. Id.
5
75. See Billion Dollar Pills, supra note 16, at 71. In America, direct-toconsumer drug advertising has increased from spending of $1.1 billion in
1997 to $4.5 billion in 2006. Id.
6
76. Michael S. Wilkes et al. Direct-to-Consumer Prescription Drug
Advertising: Trends, Impact, and Implications, HEALTH AFF., Mar.–Apr. 2000,
at 110, 112.
7
77. Big Bucks, Big Pharma, supra note 64.
8
78. Id. (transcribing a number of typical advertisements).
9
79. Id.
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prescription from their doctors.80 This effectively means that
these “patients” prescribed their own treatment for what
they diagnosed as a medical condition requiring that
treatment. As such factors increase consumer demand,
advertising budgets at the pharmaceutical companies also
increase.81
Direct-to-consumer advertising also reflects the
unbalanced priorities of the companies. Instead of
continuing to develop and research new drugs, as well as
improve old ones, the pharmaceutical companies spend
overwhelming amounts of their budgets on advertising.82
This spending only furthers the need of the pharmaceutical
companies to search for the next blockbuster drug, instead
of developing more effective treatments for common
diseases.83 Related to this issue is the need of the
pharmaceutical companies to extend patent life in order to
maintain the monopoly on a certain drug.84 In order to
extend the patent, pharmaceutical companies will find a
new use for an existing drug.85 Then they market the drug
for its new use. This marketing requires heavy promotion of
the drug,86 and further evidences the misalignment between
the interests of the pharmaceutical companies and those
who purchase the products they produce.

0

80. Wilkes et al., supra note 76, at 110–13.
81. Id.
2
82. PATTISON & WARREN, supra note 19, at 5 .
3
83. From 1989 through 2000, of the 1,035 new drugs approved only 24%
were given priority FDA review. This suggests that only those 24% were
considered improvements to existing remedies, because such new
developments are commonly given priority review. It is likely that the
overwhelming majority of research and development focuses on so called
“me-too” drugs which are copies of previously successful drugs. Me-too
drugs cost much less to develop because they involve only tweaks to
existing drugs. Thus, the pharmaceutical companies are able to increase
their spending on advertising, as 76% of their research and development
goes to drugs that cost less to develop. Id.
4
84. A pharmaceutical company’s patent on a certain drug creates a
monopoly on that drug. This monopoly is quite lucrative, so much so that
when Eli Lilly’s patent on Prozac was cut short by three years, Lilly’s stock
dropped 30% on the same day. Matthew Herper, Drug Patent Peril,
FORBES.COM,
Jan.
26,
2005,
http://www.forbes.com/technology/2005/01/26/cx_ mh_0126patents.html.
5
85. Big Bucks, Big Pharma, supra note 64.
6
86. Id.
1
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Pharmaceutical companies push unneeded drugs to
those who can afford them, and withhold desperately
needed drugs from those who cannot afford them. The
power to cure and save is outweighed by the obligation to
earn. Ethically, the corporate structure that mandates the
responsibility to maximize profits needs to be reformed.
II. CORPORATE SOCIAL RESPONSIBILITY AS THE CURE
Corporate social responsibility (CSR) can cure the ills of
the pharmaceutical companies, because it will implement
new ethics in the corporate structure that recognize broader
duties beyond those owed to shareholders.
A. DIVERGENT POSITIONS

OF

CSR

The corporate governance debate dates back to the
1930s when Adolf Berle and Merrick Dodd argued whether a
corporation owes a duty to society as a whole or just to its
shareholders.87 Berle argued that managers of the
corporation owed a duty to the shareholders because the
shareholders own the corporation.88 Berle saw the
managers as agents, or trustees, who owed a fiduciary duty
to the shareholders to maximize shareholder profits.89 Dodd
held a divergent view, arguing that the corporation should
focus, not only on the interests of its shareholders, but on
the interests of its employees, consumers, and the general
public.90 He noted that public opinion was causing the law
to change in some areas to a view in which the corporation
had a duty of social service in addition to profit making.91
The correlative modern views are known as the
7

87. See generally A.A. Berle, Jr., Corporate Powers as Powers in Trust, 44
HARV. L. REV. 1049 (1931); E. Merrick Dodd, Jr., For Whom Are Corporate
Managers Trustees?, 45 HARV. L. REV. 1145 (1932).
8
88. Berle, supra note 87, at 1049 (“It is the thesis of this essay that all
powers granted to a corporation are necessarily . . . exercisable only for
the ratable benefit of all shareholders as their interest appears.”).
9
89. Id.
0
90. See Dodd, supra note 87, at 1160.
1
91. Id. (“[T]he law has already reached the point . . . where it compels
business enterprises to recognize to some extent the interests of other
persons besides their owners.”).
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standard shareholder-oriented model92 and the stakeholderoriented model.93 The standard shareholder-oriented model
(“shareholder” model or “standard” model) adheres to
Berle’s view that the role of corporate managers is to
maximize shareholder profits.94 The stakeholder-oriented
model adheres to Dodd’s alternative construction of a
corporation’s duty, expanding his argument to align with
CSR.95
The stakeholder approach to corporate governance is
analogous to the theory of CSR. CSR focuses on the
communities in which the corporation operates or conducts
business, the environment, labor rights, human rights in
general, and ethics.96 This Article focuses on the human
rights and ethical aspects of CSR. These elements of CSR
can change the negative aspects of pharmaceutical
companies discussed in Part I. The goal is to implement CSR
in the pharmaceutical companies, shifting the corporation’s
duty from a shareholder approach to a stakeholder
approach. Such a major change would shift the focus of the
pharmaceutical companies to protecting the health of their
customers and providing necessary medicine to all
regardless of ability to pay. A change of this sort recognizes
the specific rights to medicine and health, as well as human
rights in general.

1. The Standard Shareholder-Oriented Model
The ethical responsibility of the pharmaceutical
companies is clear because they, along with treating
physicians, provide treatments to save lives. Yet there are
many instances of deaths, either because people cannot get
the right treatment, or they receive the wrong treatment.
There are further instances of people who receive treatment
suffering from harmful side effects. Though pharmaceutical
2

92. See generally Hansmann & Kraakman, supra note 4, at 440–43
(discussing the dominance of the standard shareholder-oriented model for
corporate governance).
3
93. See Generally Cynthia A. Williams, Corporate Social Responsibility in
an Era of Economic Globalization, 35 U.C. DAVIS L. REV. 705, 713–14 (2002)
(discussing various positions of scholars on corporate social responsibility,
as well as the stakeholder-oriented model providing insufficient
accountability).
4
94. Id. at 708.
5
95. Id. at 716.
6
96. Id.
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companies are not solely to blame for these issues, as
doctors prescribe the medicines that the FDA approves, the
pharmaceutical companies are most in need of reform due
to their misalignment of interests with that of their
customers.
Both the United Nations and the World Health
Organization recognize health as a fundamental human
right.97 In that light, adopting CSR that recognizes human
rights would be an effective means to end the harmful
profits-oriented
approach
currently
found
in
the
pharmaceutical
companies.
The
priority
of
the
pharmaceutical companies must change from maximizing
profits to maximizing human health. To undergo this change
there must be a shift away from the current model which
solely requires the board of directors to provide
shareholders with a fair return on their investment, and
thus requires the board to focus on maximizing profits.98
As seen from the examples discussed in Part I, when the
pharmaceutical companies strive to maximize profits, they
fail to always provide ethical health treatment to all those
who need it. The corporate structure of maximizing profits
results in an inconsistency between the pharmaceutical
companies and the expectations of those who need
treatment, believe their treatment will make them better, or
believe that health is a human right.
The common model of corporate governance, the one
found in the United States, and in U.S. pharmaceutical
companies, is the shareholder model.99 The American Law
Institute’s Principles of Corporate Governance state that a
corporation’s objective is to increase corporate profit as well
as shareholder gain.100 This model of corporate governance
developed in the United States as business and industry
grew.101 As their businesses grew, owners could not fully
622

7

97. UNAIDS Joint United Nations Programme on HIV/AIDS, Human Rights,
http://www.unaids.org/en/PolicyAndPractice/HumanRights/default.asp (last
visited Feb. 28, 2008); World Health Organization, Health and Human
Rights, http://www.who.int/hhr/en/ (Last visited Feb. 28, 2008) (“WHO
Constitution: ‘the enjoyment of the highest attainable standard of health
is one of the fundamental rights of every human being.’”).
8
98. Williams, supra note 93, at 717.
9
99. See Hansmann & Kraakman, supra note 4, at 440–41.
0
100.PRINCIPLES OF CORPORATE GOVERNANCE: ANALYSIS AND RECOMMENDATIONS § 2.01(a)
(1994).
1
101.See Mark J. Roe, Some Differences in Corporate Structure in
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fund all their endeavors, so they sold shares of their
businesses to any willing purchaser. This model resulted in
shareholders who were distant from the operations of the
business. These shareholders lacked the expertise in the
business to monitor the managers. What developed was a
system where the shareholders were not involved in the
operations of the business but were owed a duty to ensure
the managers were looking after their financial interests.102
The most prevalent form of CSR under the shareholder
model is to do everything possible, within the confines of
the law, to maximize shareholder wealth.103 This view relies
on contract and regulatory law to protect the other
constituencies affected by the corporation.104 This type of
CSR considers the corporation to have fulfilled its obligation
to society by bolstering the economy and tax base.105 Thus,
the shareholder model does not consider it necessary for
the corporation to address other societal concerns
addressed by the stakeholder model of CSR.

2. The Stakeholder Model of CSR
Unlike the shareholder model, the stakeholder model
mandates broader duties beyond those owed to share
owners of the corporation.106 CSR is recognized as a means
for a company to integrate economic, environmental, and
social concerns while addressing both shareholder and
stakeholder concerns.107 This definition embodies making
Germany, Japan, and the United States, 102 YALE L.J. 1927, 1933 (1993).
2
102.See generally id. at 1936–41 (contrasting the shareholder structure
in Germany and Japan with that of the United States in which
intermediaries hold a large percentage of shares which allows these
institutions to share the power structure with the corporation and its
managers).
3
103.See Williams, supra note 93, at 708.
4
104.See id. at 714 (identifying employment contracts, anti-discrimination
laws, and environmental protection laws, as some of those protections).
5
105.See id.
6
106.See generally, Ilias Bantekas, Corporate Social Responsibility in
International Law, 22 B.U. INT’L L.J. 309 (2004) (explaining the sources of
CER for multinational enterprises in the context of a global economy);
Upendra Baxi, Market Fundamentalism: Business Ethics at the Altar of
Human Rights, 5 HUM. RTS. L. REV. 1 (2005) (discussing the ramifications of
the Norms on the Responsibilities of Transnational Corporations and Other
Business Enterprises with Regard to Human Rights on businesses and
CSR).
7
107.See Industry Canada, What is CSR?, http://www.ic.gc.ca/epic/site/csrrse.nsf/en/h_rs00094e.html (last visited May 1, 2008).
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decisions not only based on economic factors, but also on
the human rights and community consequences of the
corporation’s actions.108 R. Edward Freemen suggests that
the corporation owes a duty to individuals or entities who
affect or are affected by corporate operations.109 He
recognizes this duty to be equally important to that owed to
the corporation’s shareholders.110
624

B. HUMAN RIGHTS

AND

ETHICAL ASPECTS

OF

STAKEHOLDER CSR

There are many international guidelines for CSR. The
focus of this Article is those CSR guidelines that recognize
human rights, ethics and the need for medical treatment.
1. United Nations
The United Nations (UN) Global Compact (the “Global
Compact”) is a voluntary global governance111 program that
focuses on implementing principles of CSR. The Global
Compact promotes CSR through ten universal principles of
human rights, labor, and the environment.112 The idea of the
Global Compact is to bring together UN agencies and civil
society to support environmental and social principles.113
The Global Compact comprises ten principles, two of which
focus on human rights.114 The principles of the UN Global
Compact are derived from the Universal Declaration of
Human Rights (UDHR).115 Article 25 of the UDHR states:
Everyone has the right to a standard of living adequate for the
health and well-being of himself and of his family, including food,
8

108.Id.
109.R. Edward Freeman & John McVea, A Stakeholder Approach to
Strategic Management 4 (Darden Bus. Sch. Working Paper No. 01-02),
available at http://ssrn.com/abstract=263511.
0
110.Id. at 10.
1
111.Global governance refers to voluntary world-wide regulatory
systems. The most notable global governance body is the United Nations,
but many other intergovernmental organizations provide guidelines, and
regulations.
See
The
Global
Governance
Group,
http://www.globalgovgroup.com/ (last visited Feb. 16, 2008).
2
112.See
United
Nations
Global
Compact,
http://www.unglobalcompact.org/
index.html
[hereinafter
Global
Compact].
3
113.Global Compact, About the Global Compact, http://www.unglobal
compact.org/AboutTheGC/index.html (last visited Feb. 16, 2008).
4
114.Global Compact, supra note 112.
5
115.Global Compact, Human Rights, http://www.unglobalcompact.org/
Issues/human_rights/index.html (Last visited Feb. 16, 2008).
9
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clothing, housing, and medical care and necessary social services,
and the right to security in the event of unemployment, sickness,
disability widowhood, old age or other lack of livelihood in
circumstances beyond his control.116

This provision of the UDHR is captured in the principles of
the UN Global Compact.117
Principles 1 and 2 of the Global Compact originate from
the 1948 UDHR. Because the UDHR and its international
protections for individual human rights were established
over a half century ago, the principles are now considered
to be international customary law.118 The objectives of the
Global Compact are to “mainstream the ten principles in
business activities around the world, and catalyze actions in
support of UN goals.”119 The Global Compact does not
include means to regulate the implementation of its
objectives and principles. The Global Compact, instead,
“relies on public accountability, transparency and the
enlightened self-interest of companies, labour [sic] and civil
society to initiate and share substantive action.”120
The UN also recognizes the need to address AIDS as a
global epidemic. In particular, the UN focuses on the
severity of the AIDS epidemic in sub-Saharan Africa, where
seventy-five percent of the world’s population infected with
AIDS lives.121 Such huge numbers of people infected with
AIDS imposes a major economic burden on that part of the
continent.122
The Declaration of Commitment on HIV/AIDS calls for
action on a global scale to address the AIDS epidemic.123
The Declaration further recognizes the importance of people
with AIDS receiving the treatment that they need by
6

116.Universal Declaration of Human Rights, G.A. Res. 217A (III), U.N. Doc.
A/810 (Dec. 10, 1948), available at http://www.un.org/Overview/rights.
html [hereinafter UDHR].
7
117.See Global Compact, supra note 112 (“Principle 1: Business should
support and respect the protection of internationally proclaimed human
rights; and Principle 2: make sure that they are not complicit in human
rights abuses.”).
8
118.Global Compact, Human Rights, supra note 115.
9
119.Global Compact, What is the UN Global Compact?, http://www.
unglobalcompact.org/AboutTheGC/index.html (Last visited Feb. 16, 2008).
0
120.Id.
1
121.Declaration of Commitment on HIV/AIDS, G.A. Res. A/RES/S-26/2, at 1
(June 27, 2001).
2
122.Id. at 2.
3
123.Id. at 1.
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emphasizing “that access to medication in the context of
pandemics such as HIV/AIDS is one of the fundamental
elements to achieve the full realization of the right of
everyone to the enjoyment of the highest attainable
standard of physical and mental health.”124 To implement
this, and other, principles of the Declaration, the UN calls
for action not only from international governments, but also
from the business and civil sectors as well. Such action
includes providing antiviral drugs to treat the disease.125
The United Nations Economic and Social Council has
further promulgated principles of CSR in its Norms on the
Responsibilities of Transnational Corporations and Other
Business Enterprises with Regard to Human Rights.”126 One
important initial aspect of the Norms is that they require
multinational corporations (MNCs) to recognize all UN and
other treaties on human rights, including the World Health
Organization principles that recognize health as a human
right.127
The principles set forth in the Norms requires MNCs to
“act in accordance with the fair business, marketing and
advertising practices and shall take all necessary steps to
ensure the safety and quality of the goods and services
they provide. . . .”128 This principle further states that MNCs
shall not “produce, distribute, market, or advertise harmful
or potentially harmful products for use by consumers.”129
Another aspect of the Norms that provides a model of
CSR particularly helpful to effect change in the
pharmaceutical companies is the definition of stakeholder.
The definition of stakeholder includes a general category of
people who are affected by the actions of the MNC.130 The
definition then elaborates on this general category, noting
that stakeholders can include people or groups who are
626

4

124.Id. at 3.
125.Id. at 4.
6
126.Norms on the Responsibilities of Transnational Corporations and
Other Business Enterprises with Regard to Human Rights, U.N. Doc.
E/CN.4/Sub.2/2003/12/Rev.2 (2003) [hereinafter Norms].
7
127.Id. at ¶ 4; World Health Organization, Health and Human Rights,
http://www.who.int/hhr/en/ (last visited Feb. 16, 2008).
8
128.Norms, supra note 126, at § F(13) (“Obligations with regard to
consumer protection”).
9
129.Id.
0
130.Id. at § I(22).
5

MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE
TECH. 607-636 (2008).

AND

LEGAL POLICY ," 9(2) MINN. J.L. SCI. &

2008]

CORPORATE SOCIAL RESPONSIBILITY
627
directly or indirectly affected by the activities of the MNC.131

2. Organisation for Economic Co-operation and
Development
The Organisation for Economic Co-operation and
Development (OECD) intends to create a strong system of
corporate governance around the world. Like the UN
Principles and Guidelines, those of the OECD are nonbinding, and voluntary.132 The OECD also suggests that
improved corporate governance will help a business to grow
and to prosper; it recognizes that business ethics and
awareness of environmental and social concerns will impact
a company’s long term success.133
The OECD principles provide a framework, or a
reference, for legislators or corporations when drafting their
corporate governance model.134 The principles are not,
however, a mandate to adopt any particular type of
corporate governance. The principles of the OECD are
intended to identify objectives of corporate governance and
create various means for achieving those objectives.135
The OECD Principles state that the board should
recognize the interests of stakeholders, applying high
ethical standards in doing so.136 The OECD recognizes the
important role of stakeholders in the long term success of
the corporation. The Principles state that where a
stakeholder’s rights are established and protected by law
the corporation should respect those rights.137 Even in areas
where stakeholder rights are not legislated, the Principles
suggest recognition of those broader interests, pointing to
the corporation’s interest in maintaining a positive
1

131.Principle 22 states that the term stakeholder includes consumer
groups, customers, and others. Thus, this definition recognizes customers
of drug companies—those who take the drugs—as people who should be
protected by the CSR program. Id.
2
132.ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT , OECD GUIDELINES FOR
MULTINATIONAL
ENTERPRISES
17
(2000),
available
at
http://www.oecd.org/dataoecd/56/36/1922428.pdf
[hereinafter
OECD
GUIDELINES].
3
133.ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT , OECD PRINCIPLES OF
CORPORATE GOVERNANCE 12 (2004) available at http:// www.oecd.org/dataoecd/
32/18/31557724.pdf [herinafter OECD PRINCIPLES].
4
134.Id. at 11.
5
135.Id. at 13.
6
136.See generally, OECD PRINCIPLES, supra note 133, at 24–29.
7
137.See generally id. at 21.
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reputation.138 The OECD omits from its definition of
stakeholder, the customer and prospective customer, only
recognizing
investors,
employees,
creditors,
and
suppliers.139
The OECD also recognizes the important role that good
health and healthcare play in economic growth.140 The
OECD 2007 Annual Report mentions that insufficient
healthcare causes unnecessary deaths, and poor health in
general, while recognizing that gaps in the access to
healthcare remain across socio-economic groups.141 The
OECD views pharmaceutical pricing and reimbursement
policies as one cause of low availability and affordability of
medicine in countries with need.142 These policies are
viewed as an inhibitors of “the global public good of
innovation in medicine.”143
628

Though the OECD Principles do not recognize the same
definition of a stakeholder as that of the Norms, the OECD
Guidelines for Multinational Enterprises (MNEs) states that
they should respect the human rights of the individuals
affected by their activities.144 This recognition is much closer
to the stakeholder CSR policies the pharmaceuticals should
adopt, because both customers and non-customers are
affected by the pharmaceutical companies.145 Furthermore,
the OECD Guidelines recognize the importance of treating
consumers in accordance with fair business, marketing, and
advertising practices as well as providing safe quality
goods.146 The standards further state that the products
should provide enough information to the customer to allow
an informed decision.147
The OECD Guidelines provide specific goals for MNEs to
8

138.Id.
139.Id.
0
140.ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT , ANNUAL REPORT 47–49
(2007), available at http://www.oecd.org/dataoecd/1/ 53/38484866.pdf.
1
141.Id. at 47.
2
142.Id. at 49.
3
143.Id.
4
144.OECD GUIDELINES, supra note 132, at 19.
5
145.As discussed in Part I, pharmaceutical companies have a great
impact on the health of their customers as well as the health of sick
people in poor countries who cannot afford medication for their diseases.
6
146.OECD GUIDELINES, supra note 132, at 25.
7
147.Id.
9
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meet in protecting their customers. The most relevant are
the health, safety and information standards. One principle
states that MNEs should ensure all products meet the
required safety standards for health, including appropriate
product warning labels.148
The OECD Principles provide helpful guidance in the
implementation of a corporate governance system. The
OECD recognizes that corporate governance may be
implemented in various ways, either through legislation,
government regulation, self regulation, or voluntary
standards.149 The first step to implement the OECD
principles is to establish an effective foundation of laws and
regulations.150 The OECD suggests monitoring the corporate
governance framework to ensure it is serving its purpose of
promoting ethical and transparent corporate governance
practices.151 The OECD recommends that laws and
regulations affecting corporate governance be implemented
efficiently and fairly. One way to achieve this is for
government and regulatory authorities to meet with
corporations and their stakeholders to assess the CSR
framework of the company.152
While the OECD suggests self-regulation as possible
means to implement CSR, it clearly prefers laws and
regulations set by a governing body.153 Self-regulation is
certainly better than no CSR at all, but it can leave
stakeholders and shareholders uncertain about the
implementation and meaning of the standards.154 This
uncertainty contributes to the OECD’s preference for
national regulation that provides a framework shareholders
and stakeholders can rely upon, and find redress in, if
something goes wrong.155

3. The European Union
The major publication that sets forth the standards of
CSR in the EU, and the means to implement those
8

148.Id.
149.OECD PRINCIPLES, supra note 133, at 29–31.
0
150.Id.
1
151.Id.
2
152.Id.
3
153.Id.
4
154.Id.
5
155.Id.
9
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standards is the 2001 European Commission Green Paper.156
The Green Paper recognizes the stakeholder approach to
CSR, but even more importantly it recognizes customers as
stakeholders and human rights as an important aspect of
CSR. The Green Paper explores the role of business in
issues generally considered to be within the public realm,
including poverty and exclusion.157
The Green Paper makes ethical treatment of customers
a part of its Corporate Social Responsibility agenda. 158 The
Green Paper touts this aspect of CSR as a way to build
company profits.159 By providing its customers with safe,
reliable, high quality products the company will build lasting
relationships with its customers.160 Of course, these lasting
relationships are fostered and brought about through the
CSR program that instilled the ethical values of providing
top quality products to customers.161
The Green Paper also discusses the importance of
recognizing human rights in CSR. Again, the Green Paper
points out that recognition of human rights can have a
positive economic effect for the company, due to the
positive image created.162 Though the human rights section
focuses primarily on fair labor standards, the Green Paper
nonetheless recognizes the importance of a corporation
having less of a negative impact on human rights in the
local community.163 The Green Paper also incorporates the
OECD Guidelines for Multinational Enterprises which
establishes standards for protecting the human rights for a
broader range of stakeholders, including anyone affected by
the activities of the corporation.164
The Green Paper also recommends to the MNEs the
establishment of codes of conduct to implement its human
630
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156.INDUSTRIAL RELATIONS AND INDUSTRIAL CHANGE, EUROPEAN COMM’N, GREEN PAPER,
PROMOTING A EUROPEAN FRAMEWORK FOR CORPORATE SOCIAL RESPONSIBILITY 12, 14 (2001),
available
at
http://ec.
europa.eu/employment_social/socdial/csr/greenpaper_en.pdf [hereinafter GREEN PAPER].
7
157.Bantekas, supra note 106, at 317.
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158.GREEN PAPER, supra note 156, at 13–14.
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159.Id.
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160.Id.
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161.Id.
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162.Id. at 14–15.
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163.Id.
4
164.Id.; see also OECD GUIDELINES, supra note 132, at 19.
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rights policies.165 A code of conduct is a set of standards
together with a pledge by the company to observe the
standards.166 To effectively implement human rights, the
codes of conduct must be established at every level of the
company. A verification scheme should also be established
to audit the effectiveness of the program.167 The Green
Paper suggests that codes of conduct emphasize continuing
gradual improvements to the standards established by the
company and to the code of conduct itself.168

III. LESSONS LEARNED:
IS CSR THE APPROPRIATE PRESCRIPTION?
One obstacle to implementing CSR is the apparent
control the pharmaceutical companies have over United
States lawmakers and regulators. The most recent evidence
of this control is the failure of the House of Representatives
to pass an effective version of The Food and Drug
Administration Amendments Act of 2007.169 This resolution
was designed to raise the standards for disclosure of drug
side effects and test results, regulate direct-to-consumer
advertising, and end conflicts of interest between the FDA
and pharmaceutical companies.170 The bill passed by the
House does none of these things; it strengthens the
pharmaceutical companies’ ties with the FDA.171 This
reversal occurred as a result of coercion from the powerful
pharmaceutical lobby, PhRMA.172 The pharmaceutical lobby
is recognized as the most powerful lobby in Washington.173
5

165. GREEN PAPER, supra note 156, at 14-15.
166.Id.
7
167.Id.
8
168.Id.
9
169.Mike Adams, FDA Tyranny to Become Law: HR 2900 Analysis,
NATURALNEWS.COM, July 12, 2007, http://www.naturalnews.com/021932.html
(discussing the passage of Food and Drug Administration Amendments Act
of 2007, H.R. 2900, 110th Cong. (2007)).
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170.Id.
1
171.Id.
2
172.Id.
3
173.“The combined worth of the world’s top five drug companies is twice
the combined GDP of all sub-Saharan Africa and their influence on the
rules of world trade is many times stronger because they can bring their
wealth to bear directly on the levers of western power.” Julian Borger,
Industry that Stalks the U.S. Corridors of Power, GUARDIAN (Manchester),
Feb.
13,
2001,
available
at
http://www.guardian.co.uk/international/story/0,3604,437212,00. html.
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Another example of PhRMA’s strength in Washington is
the failure of The Prescription Drug User Fee Act (PDUFA)
that was intended to strengthen the FDA system of
approving drugs.174 Instead the law created a sense that the
FDA is actually accountable to the drug companies, which
results in less drug safety regulation.175 Additionally, PDUFA
has minimal funding and this limits the FDA’s testing and
research of drug safety.176 Not only does this legislation not
help to regulate drug safety, but commentators argue that
the Act has the opposite effect.177
I raise these issues here to demonstrate the difficulties
that lie ahead in mandating the adoption of CSR principles
in pharmaceutical companies. To pass the laws establishing
CSR guidelines, legislators will have to overcome the
pharmaceutical lobby. With enough ground swell and
consumer support for new CSR principles, PhrMA may be
forced to consider the negative impact that opposing
human rights and consumer protection laws will have on
public opinion of drug companies.
632

A. CSR APPLIED

TO

PHARMACEUTICAL COMPANIES

There are two fundamental aspects of CSR to consider
in examining the various models capable of addressing the
problems identified with the pharmaceutical companies:
who the CSR protects, and what rights CSR protects. The
appropriate model of CSR will protect both customers and
non-customers. CSR should protect human rights of these
groups specifically recognizing that health is a human right.
The
pharmaceutical
companies must
recognize
stakeholders, not just shareholders. Adopting a system of
CSR that recognizes and protects the stakeholders will shift
pharmaceutical companies from the current bottom line
4

174.Sidney Wolfe, Ben Peck & Frank Clemente, Comments on: The
Prescription Drug User Fee Act (PDUFA), PUBLIC CITIZEN, Jan. 25, 2002, http://
www.citizen.org/publications/release.cfm?ID=7145.
5
175.Avorn, supra note 53.
6
176.The FDA proposed to devote only $29.3 million to the drug-safety
program. This amounts to 6.7% of the $437.8 million in user-fee revenue.
Compare this to the $188.5 billion that was spent on prescription drugs in
the United States in 2004, and the $11.9 billion spent on pharmaceutical
advertising. Sean Hennessy & Brian L. Strom, PDUFA Reauthorization—
Drug Safety’s Golden Moment of Opportunity?, 356 NEW ENG. J. MED. 1703,
1703 (2007).
7
177.Id.
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model to that of ethics and human rights. The stakeholder
model implemented must recognize both customers and
individuals affected by the companies’ activities as
stakeholders. The broadest recognition of a stakeholder
group is found in the OECD Guidelines which states that
MNC’s should respect the human rights of those affected by
their activities.178 This broad interpretation of a stakeholder
includes the groups of people who need to be protected
from the pharmaceutical companies, both customers and
poor people who cannot afford to be customers.
When it comes to the issues discussed in Part I, it is
clear that the concern is to help customers, in addition to
people who need a medicine, but who do not have access to
it. Customers need protection from side effects, overprescription, and direct-to-consumer advertising. Those who
desire medication need to gain access to the drugs they
need in order to live. The OECD’s broad recognition covers
these groups and makes for a good starting point for an
appropriate model of CSR.
Both the Norms and the OECD Guidelines establish a
requirement that a corporation conduct its business
recognizing fair business, marketing and advertising
practices, and that companies should provide safe quality
products to their customers.179 This principle addresses the
protection of the customer. Application of this principle
could be used to limit direct-to-consumer advertising,
require fewer harmful side effects or increased patient
notification regarding side effects, and create more
stringent prescription standards to ensure the benefit to the
patient outweighs the potential risks.
In the face of a fair advertising requirement, direct-toconsumer advertising will either undergo a fundamental
change, or end altogether. Many do not consider this
advertising to be fair due to its effects on the consumer and
prescription practices.180 CSR principles should make
advertising more fair. Direct-to-consumer advertising would
be acceptable as long as it was considered fair to the
consumer. These advertisements would have to be
8

178.OECD GUIDELINES, supra note 132, at 19.
179.Id.; Norms, supra note 126.
0
180.Direct-to-consumer advertising may encourage patients to pressure
their physicians to prescribe specific medications. Wilkes et al., supra note
76, at 120.
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subjected to a heightened standard to ensure that they
were not misleading and did not lead to self diagnoses.
Overall, the goal of the advertising should be to improve
patient health, not to improve the shareholders’ bottom
line. This goal is consistent with not only the fairness
standard found in the OECD Guidelines and the Norms, but
also with the standards of fair business practices and
providing safe quality products to consumers.
Additionally, by requiring safe quality products, the
consumer is protected from dangerous prescriptions. This
would call for higher regulatory standards to ensure the
drug’s side effects did not outweigh its benefits. The CSR
model could implement such regulatory standards. A
standard could focus on informing patients about risks,
creating a heightened scrutiny of the risks of taking the
drug, and weighing the risks against the benefits. By
requiring such a standard, the patient would be better
informed of the risks associated with the drug, and the
pharmaceutical companies would have less influence over
the doctors’ prescriptions. This would have a chilling effect
on over-prescription and lead to overall consumer
protection.
The CSR program should also protect those who are
affected by the activities of the pharmaceutical companies
but are not customers. Those affected by the activities of
the company are recognized as stakeholders in the various
models of CSR. This includes those who need drugs but do
not have access to them either because the drugs are too
expensive or because the needed treatments have become
ineffective. This group includes the AIDS patients in Brazil
and South America, the people who suffer from tropical
diseases in Africa like sleep sickness, and the boy in India
whose family could not afford the medicine to save him. The
activities of the pharmaceutical companies affect these
people because the pharmaceutical companies control the
means to make them healthy and to save their lives. This
profound effect on these non-customers’ lives qualifies
these people as affected by the activities of the
pharmaceutical companies.
Non-customers are recognized as stakeholders to whom
the pharmaceutical companies owe a duty, and thus
companies should provide protection for these people.
Coupling this recognition of non-customers as stakeholders
634
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with the human rights aspect of CSR truly protects these
people. The human rights aspect of CSR includes the right
to health and to medicine as established in both the UDHR
and the WHO Health and Human Rights section.181 The
recognition of the right to health and medicine as a human
right will compel the pharmaceutical companies to protect
those rights by providing treatment to those who need it.
Thus, the pharmaceutical companies would, through CSR,
protect human rights including the right to health and
medicine. The human rights aspect of CSR coupled with the
broad definition of a stakeholder, which includes noncustomers, would effectively require the pharmaceutical
companies to find a way to provide low cost, effective
medicine to those who could not otherwise afford it.

B. CHALLENGES

TO IMPLEMENTING

CSR

The hurdle in the CSR debate is not whether the
principles would work to cure the issues raised in Part I, as
the discussion above shows that those issues would be
effectively addressed through adopting the CSR principles.
The hurdle is how to implement the principles. All of the
CSR models discussed are voluntary. They suggest means
of implementation, such as adopting codes of conduct or
adhering to the laws of the host country, but they do not
establish a way to mandate CSR in a country that does not
recognize CSR in its corporate governance. It would be
especially difficult to establish CSR as a mandatory law that
applies to companies that have a powerful lobby and will
fight the regulation.
The CSR rules that are applicable to the pharmaceutical
companies must be mandatory. If they are voluntary, it is
likely that the pharmaceutical companies will continue to
value shareholder wealth over stakeholder health. As
alluded to in describing HR 2900 and PDUFA, the
pharmaceutical companies have an aversion to regulations.
If CSR principles were promulgated, but voluntary, it seems
likely that the pharmaceutical companies would not adopt a
CSR program. Therefore, CSR must be mandatory.

1

181.UDHR, supra note 116; World Health Organization, Health and
Human Rights, http://www.who.int/hhr/en/ (last visited Feb. 28, 2008).
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CONCLUSION
Pharmaceutical company actions can be harmful to both
their customers, by over-prescription, harmful side effects,
and direct-to-consumer advertising, and to non-customers,
by these people not having access to needed treatment or
the treatment that they do have being ineffective. Models of
CSR address these issues, and through a model of CSR that
incorporates the principles discussed above, the harms of
the pharmaceutical companies could be cured. The major
challenge to implementing a CSR program to cure these
issues is the powerful pharmaceutical lobby in Washington.
One potential way to encourage companies to adopt
CSR would be for the United States Government to give
corporate tax benefits for implementing CSR.182 Such a
voluntary program would strike a balance between the
shareholder-oriented approach and the stakeholder
approach. The shareholders would benefit in that the
corporation received favorable tax incentives. Stakeholders
would benefit from the implementation of CSR. Though such
a means of implementing CSR is not mandatory it would
create motivation for pharmaceutical companies to
implement CSR.
Added motivation for pharmaceutical companies to
further increase CSR beyond what is adopted for tax breaks
would then come from the market. If consumers began to
buy products from the companies that implemented CSR,
the market would drive further implementation of CSR.183
Such increased popularity in the market would drive up
sales and result in increased profits to benefit shareholders.
Thus, CSR would not only benefit stakeholders, but it would
also benefit shareholders.
2

182.Similar tax incentives already exist for encouraging environmental
friendly corporate practices. See generally 26 U.S.C. § 179D (2000)
(deduction available for energy efficient commercial buildings); 26 U.S.C. §
48 (2000) (tax credit available for use of solar and other renewable energy
sources).
3
183.A study found that roughly 70% of the people polled found a
company’s public health impact important vs. about 40% who found it
important for a company to deliver value to its shareholders. FLEISHMANHILLARD INT’L COMMC’NS, RETHINKING CORPORATE SOCIAL RESPONSIBILITY 8–10 (2006),
available at http://www.csrresults.com/FINAL_Full_Report.pdf

